Methods for treating dry eye

• US 20030109509A1
• Filed: 09/26/2002
• Published: 06/12/2003
• Est. Priority Date: 10/11/2001
• Status: Abandoned Application

• Current Assignee: Alcon Incorporated
• Original Assignee: Alcon Incorporated
• Inventors: Yanni, John M., Gamache, Daniel A., Van Duzee, Barry F.
• Application Number:
  US10/255,219
• Publication Number:
  US 20030109509A1
• Time in Patent Office: Days
• US Class Current: 514/171
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

Methods of treating dry eye by administering fixed combinations of MUC-1 secretagogues, such as HETE derivatives, and anti-inflammatory steroids are disclosed.

Claims

1. A composition for the treatment of dry eye and other disorders requiring the wetting of the eye comprising a pharmaceutically acceptable carrier, a pharmaceutically effective amount of an anti-inflammatory steroid and a pharmaceutically effective amount of a MUC-1 secretagogue.

2. The composition of claim 1 wherein the anti-inflammatory steroid is selected from the group consisting of rimexolone;

loteprednol;

medrysone; and

hydrocortisone.

3. The composition of claim 1 wherein the MUC-1 secretagogue is a HETE derivative selected from the group consisting of the compounds of formulas II-XIV and pharmaceutically acceptable salts, esters and amides thereof, wherein

4. The composition of claim 2 wherein the pharmaceutically effective amount of anti-inflammatory steroid is 0.001 to 1%.

5. The composition of claim 3 wherein the pharmaceutically effective amount of MUC-1 secretagogue is 0.00001 to 0.1%.

6. The composition of claim 1 wherein the MUC-1 secretagogue is 15(S)-HETE and the anti-inflammatory steroid is rimexolone.

7. A method of treating dry eye or other disorders requiring the wetting of the eye comprising topically administering to the eye a composition comprising a pharmaceutically acceptable carrier, a pharmaceutically effective amount of an anti-inflammatory steroid and a pharmaceutically effective amount of a MUC-1 secretagogue.

8. The method of claim 7 wherein the anti-inflammatory steroid is selected from the group consisting of rimexolone;

loteprednol;

medrysone; and

hydrocortisone.

9. The method of claim 7 wherein the MUC-1 secretagogue is a HETE derivative selected from the group consisting of the compounds of formulas II-XIV and pharmaceutically acceptable salts, esters and amides thereof, wherein

10. The method of claim 8 wherein the pharmaceutically effective amount of ocular surface selective steroid is 0.001 to 1%.

11. The method of claim 9 wherein the pharmaceutically effective amount of MUC-1 secretagogue is 0.00001 to 0.1%.

12. The method of claim 7 wherein the MUC-1 secretagogue is 15(S)-HETE and the anti-inflammatory steroid is rimexolone.